Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs METRONIDAZOLE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
Trichomoniasis,Bacterial vaginosis,Anaerobic infections (intra-abdominal, gynecologic, skin and skin structure),Pelvic inflammatory disease (in combination with other antibiotics),Pseudomembranous colitis (Clostridioides difficile infection),Rosacea (topical),Helicobacter pylori eradication (in combination therapy),Crohn's disease (perianal fistulas, off-label),Giardiasis (off-label)
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
Hepatic metabolism via oxidation (CYP450 enzymes) and glucuronidation; major metabolites include hydroxy-metronidazole (active).
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
<20%, primarily to albumin.
<20% bound to plasma proteins.
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
0.6-1.1 L/kg; wide distribution including CNS, abscesses, and bone.
Oral: 100% (nearly complete absorption).
Oral: 80-100%; IV: 100%.
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, administer 500 mg IV every 12 hours. Metronidazole and metabolites are removed by hemodialysis; administer after dialysis session.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose by 50% and consider extended interval (e.g., 500 mg IV every 8-12 hours). Child-Pugh Class C: Reduce dose by 75% (e.g., 250 mg IV every 12 hours or 500 mg IV every 24 hours).
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Neonates: 15 mg/kg IV loading dose, then 7.5 mg/kg IV every 12-24 hours depending on gestational age. Infants and children: 10 mg/kg IV every 6-8 hours; maximum 4 g/day. For serious infections, up to 15 mg/kg IV every 6 hours.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
No specific dose adjustment; monitor renal function due to age-related decline. For Cr Cl <10 m L/min, adjust per renal guidelines. Caution with prolonged use due to potential neurotoxicity.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
Carcinogenicity in animal studies; reserved for indications where other therapies have been inadequate.
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Carcinogenicity (animal data), seizures and peripheral neuropathy (especially with high doses or prolonged use), disulfiram-like reaction with alcohol, methemoglobinemia, QT prolongation, hepatic impairment (dose adjustment recommended), pregnancy (avoid in first trimester unless essential), lactation (use caution).
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
Hypersensitivity to metronidazole or nitroimidazole derivatives, first trimester of pregnancy (unless alternative therapies unavailable), concomitant use with disulfiram (within 2 weeks), concomitant use with alcohol or propylene glycol-containing products.
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
Alcohol must be strictly avoided during therapy and for at least 48 hours after completion to prevent a disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions; however, taking with meals can reduce gastrointestinal upset.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
Metronidazole crosses the placenta. First trimester: studies show no consistent increased risk of major malformations, but some reports suggest possible association with cleft lip/palate; avoid unless essential. Second and third trimesters: generally considered safe for short-term use; no evidence of significant fetal harm.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9; infant exposure is about 10-20% of maternal dose. Avoid high-dose or prolonged use; after a single 2 g dose, withhold breastfeeding for 12-24 hours; for standard doses, caution advised, though AAP considers compatible.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
No routine dose adjustment required in pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma protein binding) may slightly alter drug levels but clinical significance not established; use lowest effective dose for shortest duration.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
Metronidazole hydrochloride is metabolized hepatically and excreted renally; dosing adjustment needed for severe hepatic impairment (Child-Pugh C). Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use; discontinue if signs appear. IV formulation contains sodium; caution in heart failure or hypertension. Drug interactions: warfarin (enhanced anticoagulation), lithium (increased toxicity), phenytoin (increased phenytoin levels), and cimetidine (decreased clearance).
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Finish the entire course of medication even if you feel better.,Avoid alcohol and any alcohol-containing products (e.g., mouthwash, cough syrup) during treatment and for 48 hours after the last dose; serious nausea, vomiting, and headache may occur.,Take with food to reduce stomach upset.,Metronidazole may cause a metallic taste; this is temporary.,Contact your healthcare provider if you experience numbness or tingling in your hands or feet.,This medication can cause dizziness; avoid driving or operating machinery if affected.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any signs of new infection, such as fever or chills.
No interactions on record
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL I.V. RTU IN PLASTIC CONTAINER vs METRONIDAZOLE HYDROCHLORIDE, answered by our medical review team.
FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. METRONIDAZOLE HYDROCHLORIDE is a Nitroimidazole Antibiotic that works by Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL I.V. RTU IN PLASTIC CONTAINER and METRONIDAZOLE HYDROCHLORIDE depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. The standard adult dose of METRONIDAZOLE HYDROCHLORIDE is: Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL I.V. RTU IN PLASTIC CONTAINER and METRONIDAZOLE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. METRONIDAZOLE HYDROCHLORIDE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: studies show no consistent increased risk of major malformations, but some reports suggest possible association with cleft lip/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.